Compare CYRX & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | MOBI |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 399.7M |
| IPO Year | 2008 | 2026 |
| Metric | CYRX | MOBI |
|---|---|---|
| Price | $15.49 | $10.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $13.31 | N/A |
| AVG Volume (30 Days) | ★ 747.6K | 98.5K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.69 | $10.55 |
| 52 Week High | $16.89 | $15.19 |
| Indicator | CYRX | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 35.10 |
| Support Level | $14.51 | $10.79 |
| Resistance Level | $16.76 | $12.68 |
| Average True Range (ATR) | 0.80 | 0.96 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 40.09 | 11.11 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.